Charles River Laboratories International, Inc. (NYSE:CRL) posted upbeat earnings for the first quarter, but lowered its FY2026 forecast on Thursday.
The company posted adjusted EPS of $2.06, beating market estimates of $1.94. The company’s sales came in at $995.830 million versus expectations of $977.486 million.
Charles River slashed its FY2026 GAAP EPS guidance from $6.30-$6.80 to $5.35-$5.85. The company also lowered its FY2026 sales guidance from $3.814 billion-$3.874 billion to $3.794 billion-$3.854 billion.
Birgit Girshick, Chief Executive Officer, said, “We are pleased to deliver on our first-quarter financial targets, and remain well positioned to generate improving results over the course of the year. Our confidence is …
This post was originally published here
